anti-CD205 mouse monoclonal, PN-15, purified

Cat. No. 691618

Available, delivery time 1-7 days


Key Features
  • Mouse monoclonal
  • Suitable for FACS, ICC/IF, IHC and WB
  • Reacts with human, monkey and rat
  • Isotype: IgG2b kappa
Product description
Quantity 1 ml (100 µg/ml)
Antibody Type Monoclonal
Host Mouse
Isotype IgG2b kappa
Conjugate Unconjugated
Application FACS, ICC/IF, IHC, WB
Purification Affinity chromatography
Reactivity Human, Monkey, Rat
Storage 2-8°C
Intended use Research use only
Clone PN-15
Immunogen Renal cortical tissue extract
Concentration 100 µg/ml
Formulation PBS with 0.02% sodium azide
UniprotID O60449 (Human), D3ZQK8 (Rat)
Synonym Lymphocyte antigen 75, Ly-75, C-type lectin domain family 13 member B, DEC-205, gp200-MR6, CD antigen CD205, LY75, CD205, CLEC13B
Tested applications Tested dilutions
Immunocytochemistry (ICC)/ Immunofluorescence (IF) 1:100-1:200 (0.5-1.0 µg/ml)
Immunohistochemistry (IHC) - frozen 1:25-1:50 (2-4 µg/ml)
Immunohistochemistry (IHC) - paraffin 1:25-1:50 (2-4 µg/ml; microwave treatment in 10 mM citrate buffer pH 6.0 recommended)
Flow Cytometry (FACS) 0.5-1.0 µg/million cells in 0.1 ml
Western Blot (WB) 1:50-1:100 (1-2 µg/ml)

PN-15 reacts with a lectin receptor like glycoprotein of 200 kDa (gp200), present in proximal renal tubules and on urothelium. The antigen is carbohydrate in nature. Other normal tissues that display the antigen include breast, parathyroid glands, thymus and epididymis. Among renal carcinomas 93% of primary and 84% of metastatic carcinomas are positive. Bladder cancers are also largely positive. Other tumor types include breast cancer, teratocarcinomas and parathyroid adenomas. The antigen, also called DEC-205, was assigned to CD205 at CD workshop VII. In the immune system it can facilitate tolerance to self-antigens through uptake of apoptosis derived material by dendritic cells, which in turn present fragments through MHC II and MHC I, either inducing or repressing immune responses, depending on the nature of concomitant signals.

Positive control: renal carcinoma, bladder carcinoma.

Q & A's

Please enter a valid email address.
Please enter a valid question.
Fields marked with * are mandatory.

There aren't any asked questions yet.
Customer Reviews

0 of 0 reviews

Leave a review!

Share your experiences with other customers.